Suggested Reading

Barbui T, Barosi G, Biregard G, et al: Philadelphia-negative classical myeloproliferative neoplasms: Critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 29:761–770, 2011.

Barbui T, Thiele J, Passamonti F, et al: Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: An international study. J Clin Oncol 29:3179–3184, 2011.

Barbui T, Thiele J, Passamonti F, et al: Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. Blood 119:2239–2241, 2012.

Cervantes F, Dupriez B, Pereira A, et al: New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113:2895–2901, 2009.

Finazzi G, Carobbio A, Thiele J, et al. Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. Leukemia 26:716–719, 2012.

Harrison C, Kiladjian JJ, Al-Ali HK, et al: JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366:787–798, 2012.

Jones AV, Chase A, Silver RT, et al: JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genetics 41:446–449, 2009.

Jones AV, Cross NC: Inherited predisposition to myeloproliferative neoplasms. Ther Adv Hematol 4:237–253, 2013.

Mehta J, Wang H, Iqbal SU, et al: Epidemiology of myeloproliferative neoplasms in the United States. Leuk Lymphoma 2013:1–6, 2013.

Mesa RA, Niblack J, Wadleigh M, et al: The burden of fatigue and quality of life in myeloproliferative disorders: An international internet-based survey of 1179 MPD patients. Cancer 109:68–76, 2007.

Moulard O, Mehta J, Fryzek J, et al: Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union. Eur J Haematol 92:289–297, 2014.

Mughal TI, Vaddi K, Sarlis NJ, et al: Myelofibrosis-associated complications: Pathogenesis, clinical manifestations, and effects on outcomes. Int J Gen Med 7:89–101, 2014.

Passamonti F, Rumi E, Pungolino E, et al: Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 117:755–761, 2004.

Passamonti F, Cervantes F, Vannucchi AM, et al: A dynamic prognostic model to predict survival in primary myelofibrosis: A study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 115:1703–1708, 2010.

Passamonti F, Maffioli M, Merli M, et al: Clinical predictors of outcome in MPN. Hemtol Oncol Clin North Am 26:1101–1116, 2012.

Passamonti F, Thiele J, Girodon F, et al: A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. Blood 120:1197–1201, 2012.

Quintas-Cardama A, Kantarjian H, Cortes J, et al: Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov 10:127–140, 2011.

Rosenthal A, Mesa RA: Janus kinase inhibitors for the treatment of myeloproliferative neoplasms. Expert Opin Pharmacother 15:1265–1276, 2014.

Stein BL, Tiu RV: Biological rationale and clinical use of interferon in the classical BCR-ABL-negative myeloproliferative neoplasms. J Interferon Cytokine Res 33:145–153, 2013.

Stubig T, Alchalby H, Ditschkowski M, et al: JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis. Leukemia 28:1736–1738, 2014.

Tefferi A, Rumi E, Finazzi G, et al: Survival and prognosis among 1545 patients with contemporary polycythemia vera: An international study. Leukemia 27:1874-1881, 2013.

Vannucchi AM, Lasho TL, Guglielmelli P, et al: Mutations and prognosis in PMF. Am J Hematol 88:141–150, 2013.

Vannucchi AM, Hagop K, Kiladjian J-J, et al: A pooled overall survival analysis of the COMFORT studies: 2 randomized phase 3 trials of ruxolitinib for the treatment of myelofibrosis. Blood 122: abstract 2820, 2013.

Vannucchi AM, Kiladjian JJ, Griesshammer M, et al: Ruxolitinib vs standard therapy for the treatment of polycythemia vera. N Engl J Med 372:426–435, 2015.

Vardiman JW, Thiele J, Arber DA, et al: The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important change. Blood 114:937–951, 2009.

Verstovsek S, Mesa RA, Gotlib J, et al: A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366:799–807, 2012.

Verstovsek S, Mesa RA, Gotlib J, et al: Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: Results of a median 2-year follow-up of COMFORT-I. Haematologica 98:1865–1871, 2013.